Overview
International law firm McDermott Will & Emery advised Heqet Therapeutics, a Turin-based start-up (a biotech spin-out from King’s College London) active in the field of regenerative medicine, in its EUR 8m Series A funding round to complete its RNA-based therapy programme for cardiac regeneration.
The group of new investors, led by Claris Ventures and 2Invest, assisted by I2I, also saw participation in the round from King’s College London, which licensed the start-up’s patents.
McDermott, Will & Emery advised the investors with a team headed by Ettore Scandale, partner in charge of the Italian corporate department, supported by associate Stefano Pardini and trainee Matteo Landini.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
